Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous bone marrow mononuclear cells plus G-CSF with percutaneous circulatory assistance for dilated cardiomyopathy
2018-001063-23Phase 2Unknown
- Sponsor
- Queen Mary Innovation Centre
- Start
- Mar 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous bone marrow derived mononuclear cells, filgrastim in dilated cardiomyopathy (DCM), heart failure (HF), sponsored by Queen Mary Innovation Centre. Status: unknown.
02
Drugs
autologous bone marrow derived mononuclear cellsfilgrastim
03
Conditions
dilated cardiomyopathy (DCM)heart failure (HF)
Beyond the preview
Go deeper on 2018-001063-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001063-23.